Moderna

MRNANasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$23.623 B

$59.17 +9.86%

Close of 7 Aug 2026

Revenue

$1.94B

#1153 by revenue

Earnings

-$2.82B

Loss-making

Shares outstanding

399,235,889

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances) — ranked by market cap

All 160 →

#4Revolution MedicinesRVMD$44.0B
#5BiogenBIIB$30.7B
#6ModernaMRNA$23.6B
#7BioNTech SEBNTX$23.5B
#8Neurocrine BiosciencesNBIX$16.6B

Where these numbers come from

Share counts and financials for Moderna are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.